Australian Operations
Include All CSL Sites


Inactivated Japanese Encephalitis Vaccine

JESPECT® is indicated for active immunisation against Japanese Encephalitis (JE) virus for persons 18 years of age and older. 

JESPECT® should be considered for use in persons who plan to reside in or travel to areas where JE is endemic (common) or epidemic (seasonal), especially during the transmission season. 

JESPECT® is indicated for persons who work whith JE virus in laboratories and in industry.
This product is available only with a doctor’s prescription.

Who is this information for?
This information is relevant in Australia and is intended for people who have been prescribed this product or health care professionals.

Consumer Medicine Information
The Consumer Medicine Information (CMI) is a leaflet written for consumers. The CMI contains information about the medicine including:
  • What this product is used for
  • How it works
  • Before and after the vaccination
  • How this product is given
  • Side effects
PDF icon Jespect Consumer Medicine Information (PDF, 40KB)

Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by Seqirus for you if you are a:
  1. qualified healthcare professional; or
  2. consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
PDF icon Jespect Product Information (PDF, 40KB)

JESPECT® is a registered trademark of Valneva Scotland Ltd

Last Updated: 03-09-2018
LinkedIn Twitter Facebook Google+
© 2019 Seqirus